JYNT — The Joint Corp.

Summary of The Joint Corp. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Performance:

  • Revenue from continuing operations: $15.2 million, up 3% year-over-year.
  • Adjusted EBITDA: $3.6 million, an increase of 7.8%.
  • System-wide sales: $140 million, down 3.9%.
  • Comparable sales (comp sales): down 3.8%.
  • Net income: $1 million for the quarter, compared to a loss of $5.8 million in 2024.
  • Unrestricted cash and cash equivalents: $23.6 million.

• Full Year 2025 Performance:

  • Revenue: $54.9 million, compared to $52.2 million in 2024.
  • Adjusted EBITDA: $13 million, up 13.9%.
  • System-wide sales: flat at $532 million.
  • Comp sales: down 0.4%.

2. Strategic Updates and Business Highlights

• Transformation Journey (Joint 2.0): On track to complete by the end of 2026, focusing on transitioning to a pure-play franchisor model.
• Refranchising Progress: Reduced corporate-owned clinics from 135 to 48, with ongoing negotiations for further refranchising.
• Marketing Strategy: Shifted focus from wellness to pain relief in messaging, enhanced national marketing efforts, and improved SEO to drive new patient acquisition.
• Patient Experience: Continued improvements in technology and patient-facing mobile app, achieving high satisfaction ratings (4.91/5).

3. Forward Guidance and Outlook

• 2026 Guidance:

  • Expected system-wide sales: $540 million to $552 million.
  • Comp sales: projected between -3% to +3%.
  • Consolidated adjusted EBITDA: $12.5 million to $13.5 million.
  • Anticipated clinic count to decline as new openings will be offset by closures.

• Long-term Vision: Plans for Joint 3.0 in 2027 to expand into new channels and markets, including international opportunities.

4. Bad News, Challenges, or Points of Concern

• Sales Decline: Q4 comp sales were lower than expected, primarily due to a decrease in new patient counts.
• Attrition Rates: While patient retention improved, new patient acquisition remains a significant challenge.
• Economic Sensitivity: The patient demographic has been affected by macroeconomic conditions, impacting their willingness to spend on services.
• Pricing Strategy: Testing of price increases has shown mixed results, with cautious implementation due to potential customer sensitivity.

5. Notable Q&A Insights

• New Patient Metrics: New patient acquisition has been the weakest area, with ongoing marketing efforts aimed at improving this metric.
• Marketing Investment: The new AI-driven SEO marketing strategy is an incremental spend, reallocating resources rather than increasing overall marketing budget significantly.
• Comp Sales Trends: Comp sales were down most in November but improved in December; expectations for better performance in the second half of 2026 due to easier comparisons and improved marketing traction.
• Operational Improvements: Focus on enhancing the patient experience and conversion rates through better training and technology integration.

Overall, The Joint Corp. is making strides in its transformation and refranchising efforts, but faces challenges in patient acquisition and sales growth that need to be addressed to meet its future goals.